Transcriptomic characterization of fibrolamellar hepatocellular carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 44, 2015, Pages E5916-E5925

  Simon, Elana P ^a   Freije, Catherine A ^a   Farber, Benjamin A ^a,b   Lalazar, Gadi ^a   Darcy, David G ^a,b   Honeyman, Joshua N ^a,b   Chiaroni Clarke, Rachel ^a   Dill, Brian D ^a   Molina, Henrik ^a   Bhanot, Umesh K ^b   La Quaglia, Michael P ^b   Rosenberg, Brad R ^a   Simon, Sanford M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Fusion gene; Genomics; Liver cancer; Pediatric cancer; Protein kinase

Indexed keywords

AURORA A KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTOME;

ARTICLE; CANCER TISSUE; CELL CYCLE REGULATION; CELL INTERACTION; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN SYNTHESIS; EXTRACELLULAR MATRIX; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; GENE CONTROL; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; NEUROENDOCRINE TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UPREGULATION; WNT SIGNALING PATHWAY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; VALIDATION STUDY;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84946601391     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424894112     Document Type: Article

References (104)

1. Edmondson HA (1956) Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 91(2):168-186.
2. Craig JR, Peters RL, Edmondson HA, Omata M (1980) Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46(2):372-379.
3. Torbenson M (2012) Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo) 2012: 743790.
4. Katzenstein HM, et al. (2003) Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97(8):2006-2012.
5. Weeda VB, et al. (2013) Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma-results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 49(12):2698-2704.
6. Kaseb AO, et al. (2013) Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85(4):197-203.
7. El-Serag HB, Davila JA (2004) Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 39(3):798-803.
8. Pinna AD, et al. (1997) Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 26(4):877-883.
9. Mavros MN, Mayo SC, Hyder O, Pawlik TM (2012) A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 215(6):820-830.
10. Malouf G, et al. (2009) Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 62(6):519-524.
11. Nerlich AG, et al. (1992) Excessive collagen formation in fibrolamellar carcinoma of the liver: A morphological and biochemical study. Mod Pathol 5(5):580-585.
12. Berman MA, Burnham JA, Sheahan DG (1988) Fibrolamellar carcinoma of the liver: An immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 19(7):784-794.
13. Ang CS, et al. (2013) Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: Data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 6(1):3-9.
14. Ward SC, et al. (2010) Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 23(9):1180-1190.
15. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149(6):1192-1205.
16. Malouf GG, et al. (2014) Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology 59(6):2228-2237.
17. Xu L, et al. (2015) Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet 24(1):50-63.
18. Agarwal VR, et al. (1998) Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab 83(5):1797-1800.
19. Hany MA, et al. (1997) A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol 28(2): 136-138.
20. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M (2007) Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 38(4):639-644.
21. Honeyman JN, et al. (2014) Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343(6174):1010-1014.
22. Darcy DG, et al. (2015) The genomic landscape of fibrolamellar hepatocellular carcinoma: Whole genome sequencing of ten patients. Oncotarget 6(2):755-770.
23. Taylor SS, Ilouz R, Zhang P, Kornev AP (2012) Assembly of allosteric macromolecular switches: Lessons from PKA. Nat Rev Mol Cell Biol 13(10):646-658.
24. Shaywitz AJ, Greenberg ME (1999) CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821-861.
25. Tremblay JJ, Hamel F, Viger RS (2002) Protein kinase A-dependent cooperation between GATA and CCAAT/enhancer-binding protein transcription factors regulates steroidogenic acute regulatory protein promoter activity. Endocrinology 143(10): 3935-3945.
26. Naumann M, Scheidereit C (1994) Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J 13(19):4597-4607.
27. Zhang M, et al. (2014) Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies. PLoS One 9(10):e109523.
28. Yu F-X, et al. (2013) Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Development 27(11):1223-1232.
29. Baert JL, Beaudoin C, Coutte L, De Launoit Y (2002) ERM transactivation is up-regulated by the repression of DNA binding after the PKA phosphorylation of a consensus site at the edge of the ETS domain. J Biol Chem 277(2):1002-1012.
30. Mao T, et al. (2011) PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism. Proc Natl Acad Sci USA 108(38): 15852-15857.
31. Lerario AM, Moraitis A, Hammer GD (2014) Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 386(1-2):67-84.
32. Baselga J, Swain SM (2009) Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463-475.
33. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11(10):R106.
34. Hänzelmann S, Castelo R, Guinney J (2013) GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7.
35. Wu Y-H, Chang T-H, Huang Y-F, Huang H-D, Chou C-Y (2013) COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene 33(26):3432-3440.
36. Jagirdar J, Ishak KG, Colombo M, Brambilla C, Paronetto F (1985) Fibronectin patterns in hepatocellular carcinoma and its clinical significance. Cancer 56(7): 1643-1648.
37. Torbenson M, et al. (2002) Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 15(8):826-830.
38. Van Eyken P, et al. (1990) Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 17(2):101-107.
39. Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15(12):1243-1253.
40. Hoshida Y, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359(19):1995-2004.
41. Sukowati CHC, et al. (2013) The expression of CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro study. PLoS One 8(10):e76830.
42. Reedijk M, et al. (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65(18): 8530-8537.
43. Kufe DW (2009) Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 9(12):874-885.
44. Ku BM, et al. (2011) CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 128(6):1316-1326.
45. Kawada M, et al. (2012) Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31(26):3111-3123.
46. Mellon PL, Clegg CH, Correll LA, McKnight GS (1989) Regulation of transcription by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA 86(13):4887-4891.
47. Yu F-X, Guan K-L (2013) The Hippo pathway: Regulators and regulations. Genes Development 27(4):355-371.
48. Chi P, et al. (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467(7317):849-853.
49. Vellanki RN, Zhang L, Volchuk A (2013) OASIS/CREB3L1 is induced by endoplasmic reticulum stress in human glioma cell lines and contributes to the unfolded protein response, extracellular matrix production and cell migration. PLoS One 8(1):e54060.
50. Denard B, Lee C, Ye J (2012) Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife 1:e00090.
51. Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297-308.
52. Hers HG (1983) The control of glycolysis and gluconeogenesis by protein phosphorylation. Philos Trans R Soc Lond B Biol Sci 302(1108):27-32.
53. Patra KC, et al. (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2): 213-228.
54. Moon J-S, et al. (2011) Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem 286(27):23808-23816.
55. McCleland ML, et al. (2013) Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 19(4):773-784.
56. Mitsushita J, Lambeth JD, Kamata T (2004) The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64(10): 3580-3585.
57. Adachi Y, et al. (2008) Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27(36): 4921-4932.
58. Loo JM, et al. (2015) Extracellular metabolic energetics can promote cancer progression. Cell 160(3):393-406.
59. Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13(1):11-26.
60. Terasaki H, Saitoh T, Shiokawa K, Katoh M (2002) Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway. Int J Mol Med 9(2):107-112.
61. Matsui A, et al. (2009) DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci 100(10):1923-1930.
62. Vinik AI, et al. (2010) NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39(6):713-734.
63. Gould VE, et al. (1987) Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 126(2):243-257.
64. van Adrichem RCS, et al. (2013) Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect 2(4):172-177.
65. Jacobsson B, Carlström A, Collins VP, Grimelius L (1989) Transthyretin in endocrine pancreatic tumors. Am J Pathol 134(2):465-471.
66. Jansen E, Ayoubi TA, Meulemans SM, Van De Ven WJ (1995) Neuroendocrine-specific expression of the human prohormone convertase 1 gene. Hormonal regulation of transcription through distinct cAMP response elements. J Biol Chem 270(25): 15391-15397.
67. Johnston SRD, Dowsett M (2003) Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer 3(11):821-831.
68. Holland DG, et al. (2011) ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3(3):167-180.
69. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182.
70. Stephens P, et al. (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431(7008):525-526.
71. Network CGA; Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330-337.
72. Cabodi S, et al. (2010) p130Cas is an essential transducer element in ErbB2 transformation. FASEB 24(10):3796-3808.
73. Northey JJ, et al. (2008) Signaling through ShcA is required for transforming growth factor beta- And Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 28(10):3162-3176.
74. Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin- dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283(49):34087-34100.
75. Michalides R, et al. (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5(6): 597-605.
76. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV (2004) Aurora A, meiosis and mitosis. Biol Cell 96(3):215-229.
77. Sen S, et al. (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94(17):1320-1329.
78. Bischoff JR, et al. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052-3065.
79. Jeng Y-M, Peng S-Y, Lin C-Y, Hsu H-C (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10(6):2065-2071.
80. Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: New targets for cancer therapy. Clin Cancer Res 12(23):6869-6875.
81. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E (2000) The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19(42):4906-4916.
82. Nakayama N, et al. (2010) Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116(11):2621-2634.
83. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF (2001) Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21(14):4773-4784.
84. Kollmann K, et al. (2013) A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 24(2):167-181.
85. Humbert PO, et al. (2000) E2f3 is critical for normal cellular proliferation. Genes Dev 14(6):690-703.
86. Andrechek ER (2015) HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Oncogene 34(2):217-225.
87. Foster CS, et al. (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23(35):5871-5879.
88. Oeggerli M, et al. (2006) E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 25(49):6538-6543.
89. McCloskey JJ, Germain-Lee EL, Perman JA, Plotnick LP, Janoski AH (1988) Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics 82(3): 379-382.
90. Carney JA, Lyssikatos C, Lodish MB, Stratakis CA (2015) Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes. Hum Pathol 46(1):40-49.
91. Zhong H, Voll RE, Ghosh S (1998) Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1(5):661-671.
92. Li W, Tan D, Zenali MJ, Brown RE (2010) Constitutive activation of nuclear factorkappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 3(3):238-243.
93. Li Q, Luo C, Löhr CV, Dashwood RH (2011) Activator protein-2α functions as a master regulator of multiple transcription factors in the mouse liver. Hepatol Res 41(8): 776-783.
94. Bulun SE, et al. (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: From bench to treatment. Pharmacol Rev 57(3):359-383.
95. Holloway KR, et al. (2013) SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol 27(3):480-490.
96. Yang JW, et al. (2008) Differential regulation of ErbB2 expression by cAMPdependent protein kinase in tamoxifen-resistant breast cancer cells. Arch Pharm Res 31(3):350-356.
97. Bastidas AC, Pierce LC, Walker RC, Johnson DA, Taylor SS (2013) Influence of Nmyristylation and ligand binding on the flexibility of the catalytic subunit of protein kinase A. Biochemistry 52(37):6368-6379.
98. Bernards R (2014) Finding effective cancer therapies through loss of function genetic screens. Curr Opin Genet Dev 24:23-29.
99. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357-359.
100. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29(1): 15-21.
101. Anders S, Pyl PT, Huber W (2015) HTSeq-A Python framework to work with highthroughput sequencing data. Bioinformatics 31(2):166-169.
102. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550.
103. Smyth GK (2005) Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor, eds Gentleman R, Carey VJ, Dudoit S, irizarry R, Huber W (Springer, New York), pp 397-420.
104. Law CW, Chen Y, Shi W, Smyth GK (2014) voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15(2):R29.